Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
CA 2126687 A1 · Owner: Merck & Co. Inc. · Inventors: Durette, Philippe L.; Goulet, Joung L.; Caldwell, Charles G.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel phosphinic acid-containing peptidyl compounds of formula (I) are found to be useful inhibitors of matrix metallonendoproteinase-mediated diseases including osteoarthritis rheumatoid, arthritis, septic arthritis tumor invasion in certain cancers, periodontal disease corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, and coronary thrombosis associated with atherosclerotic plaque rupture. These inhibitors may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 15, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 15, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 15, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.